Skip to main content

Table 3 Parent-reported outcomes at cross-sectional visit in patients still receiving ETN

From: Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

 

No assessed

 

Median (IQR) physical function scorea

420

0 (0; 3)

No (%) of patients with physical function score = 0

420

220 (52.4)

Median (IQR) HRQL scoreb

417

2 (0; 5)

No (%) of patients with HRQL score > 1 DS above the mean of healthy children

417

92 (22.1)

Median (IQR) HRQL PhH scorec

417

1 (0; 3)

No (%) of patients with HRQL PhH score > 1 DS above the mean of healthy children

417

203 (48.7)

Median (IQR) HRQL PsH scorec

417

1 (0; 3)

No (%) of patients with HRQL PsH > 1 DS above the mean of healthy children

417

82 (19.7)

Median (IQR) VAS well-beingd

420

0.5 (0; 3)

No (%) of patients with VAS well-being = 0

420

193 (46)

Median (IQR) VAS paind

420

0 (0; 2,5)

No (%) of patients with VAS pain = 0

420

215 (51.2)

No (%) of patients with VAS pain ≤1

420

289 (68.8)

No (%) of patients with VAS pain from 1.5 to 5

420

99 (23.6)

No (%) of patients with VAS pain >5

420

32 (7.6)

Median (IQR) VAS disease activityd

420

0 (0; 2)

No (%) of patients with VAS disease activity = 0

420

224 (53.3)

No (%) of patients with no morning stiffness

420

319 (76)

Disease activity state

 No (%) of patients with remission

421

286 (67.9)

 No (%) of patients with continued activity

421

86 (20.4)

 No (%) of patients with disease flare

421

49 (11.6)

No (%) of parents satisfied with their child’s illness outcome

399

330 (82.7)

  1. IQR interquartile range, HRQL health-related quality of life, PhH Physical Health, PsH Psychosocial Health, VAS visual analog scale
  2. aScore ranges from 0 (no disability) to 30 (maximum disability)
  3. bScore ranges from 0 to 30, higher scores indicate worse HRQL
  4. cScore ranges 0–15, higher scores indicate worse HRQL
  5. dAll VAS range from 0 (best) to 10 (worst)